During the 2024–2025 biennium, Cuba incorporated vaccination against the human papillomavirus (HPV) for 9‑year‑old girls into its national immunization schedule for the first time, marking a key milestone in the prevention of cervical cancer and in advancing the PAHO Disease Elimination Initiative. The campaign, launched in October 2025, had reached 76.7% coverage among the target population by the end of the year, demonstrating the capacity of the national health system to efficiently introduce new health technologies.

This introduction was made possible through financing from Gavi, the Vaccine Alliance, and sustained technical support from PAHO. The latter’s contribution was comprehensive, encompassing both strategic planning and operational implementation. In addition to supporting the financing of 50% of the vaccine doses, the Organization accompanied essential preparatory activities, including strengthening the cold chain, training health personnel on vaccination protocols, campaign planning, surveillance of adverse events following immunization (AEFIs), and standardization of vaccine administration techniques.

This achievement contributes to the future reduction of the incidence and mortality of cervical cancer, increases access to preventive services, and consolidates national immunization capacities, with lasting impacts on women’s health and the performance of the health system.

Photo caption: A child being vaccinated by a nurse